Two of the most studied peptides in tissue repair research — BPC-157 and GHK-Cu — are often discussed in the same breath, yet they operate through entirely different mechanisms. This article examines what the current body of research actually shows about each compound, how their pathways compare, and why understanding the distinction matters for serious researchers.
What Are These Compounds?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a naturally occurring sequence found in human gastric juice. It consists of 15 amino acids and has been extensively studied in preclinical models for its effects on wound healing, tendon repair, and tissue regeneration.
GHK-Cu is a naturally occurring copper-binding tripeptide — glycine-histidine-lysine — first isolated from human plasma. It is found in various tissues and has been the subject of substantial research regarding its role in skin biology, wound repair, anti-inflammatory signalling, and gene expression modulation.
Both are classed as research compounds. Neither is approved for human therapeutic use. What follows is a summary of the peer-reviewed and preclinical literature only.
Mechanism: Where They Differ
BPC-157 — Angiogenic and Tendon-Focused Pathways
The most consistent finding in BPC-157 research is its apparent interaction with the nitric oxide (NO) system and its upregulation of vascular endothelial growth factor (VEGF). Studies in rodent models have repeatedly demonstrated accelerated healing of tendons, ligaments, and muscle tissue, with researchers pointing to angiogenesis — the formation of new blood vessels — as a primary driver.
BPC-157 has also shown interaction with the growth hormone receptor system, and several studies suggest modulation of dopaminergic and serotonergic signalling, though the relevance of these findings to tissue repair specifically remains an area of active investigation.
Notably, BPC-157 appears stable in gastric acid, which has led to significant research interest in its effects on gastrointestinal tissue — including models of inflammatory bowel conditions, fistula repair, and ulcer healing.
GHK-Cu — Gene Expression and Extracellular Matrix Remodelling
GHK-Cu operates through a substantially different mechanism. The copper component is central to its activity: copper is an essential cofactor for lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin fibres in the extracellular matrix (ECM).
Research by Loren Pickart and colleagues, along with more recent genomic studies, has demonstrated that GHK-Cu modulates the expression of over 4,000 human genes — broadly in a direction associated with tissue repair, anti-inflammatory signalling, and antioxidant defence. This includes upregulation of collagen synthesis genes and downregulation of genes associated with inflammatory cascades and matrix degradation.
GHK-Cu has also demonstrated the ability to attract immune cells to wound sites, stimulate fibroblast proliferation, and promote the synthesis of glycosaminoglycans — the structural molecules that give connective tissue its tensile integrity.
The Research Landscape
BPC-157: Predominantly Preclinical
The BPC-157 literature is substantial but almost entirely confined to in vitro and rodent studies. The compound has been investigated in models covering tendon repair, bone healing, corneal injury, spinal cord damage, and gastrointestinal pathology — with consistently positive results across model types.
The absence of completed human clinical trials is the principal limitation of the current evidence base. While researchers have noted the stability, apparent tolerability, and pleiotropic effects of BPC-157 in animal models, translation to human biology remains unconfirmed.
GHK-Cu: A Broader Evidence Base
GHK-Cu has a longer research history and a somewhat broader evidence footprint. It has been studied in wound healing contexts since the 1970s, and its role in skin biology is among the better-characterised areas of peptide research. Human studies — while limited in scale — have examined GHK-Cu in the context of wound dressings, burn repair, and cosmetic skin research.
The genomic profiling work published in the 2010s significantly expanded understanding of GHK-Cu's potential scope, suggesting mechanisms that extend well beyond simple wound healing into broader tissue homeostasis and cellular repair signalling.
Comparing Key Areas of Research Interest
| Research Area | BPC-157 | GHK-Cu |
|---|---|---|
| Tendon & ligament repair | Strong preclinical evidence (rodent models) | Limited direct research |
| Skin & wound healing | Studied, particularly GI tissue | Extensively studied; broader human literature |
| Collagen synthesis | Indirect via angiogenesis & VEGF | Direct via gene expression & copper cofactor activity |
| Anti-inflammatory signalling | Observed in multiple models | Genomic evidence; downregulation of inflammatory genes |
| Angiogenesis | Primary documented mechanism | Secondary; less central to proposed mechanisms |
| Human clinical evidence | Minimal to none | Limited; some wound healing studies |
| Systemic effects | CNS, GI, vascular — broad | Primarily tissue-local; genomic scope |
What Researchers Should Understand
The framing of BPC-157 vs GHK-Cu as competing compounds misses an important point: they are not interchangeable, and their research applications are distinct.
BPC-157 research has focused heavily on structural tissue repair in musculoskeletal and gastrointestinal contexts, with angiogenesis as a likely primary driver. Its effects appear rapid in model systems and broad in scope — a characteristic that has made it a subject of significant interest but also one that demands careful interpretation, given the complexity of its apparent mechanisms.
GHK-Cu research is more precisely mechanistic: the compound's effects on collagen cross-linking and gene expression are better understood at a molecular level, and its skin biology applications are among the most evidence-supported areas of peptide research outside of pharmaceutical development.
For researchers studying ECM remodelling, skin biology, or collagen-related pathways, GHK-Cu offers a more mechanistically grounded starting point. For researchers focused on tendon, ligament, or gastrointestinal tissue models, BPC-157's preclinical literature is more directly relevant.
A Note on Research Standards
Both compounds are supplied by Eira London strictly for research purposes. Neither BPC-157 nor GHK-Cu is approved for human therapeutic use. No claims are made regarding efficacy, safety in humans, or suitability for any medical application.
All Eira London compounds are batch-tested and accompanied by Certificate of Analysis documentation. Researchers are encouraged to review the primary literature independently and design studies in accordance with applicable institutional and regulatory requirements.
Further Reading
- Sikiric et al. (2018). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design.
- Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International.
- Pickart L, Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences.
- Chang CH et al. (2011). The促 promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology.
Research Use Only. Eira London products are supplied for research purposes only. They are not intended for human consumption, medical use, diagnosis, treatment, prevention or cure of any disease.